English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 10 April 2025, 12:57 HKT/SGT
Share:
Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy

SINGAPORE, Apr 10, 2025 - (ACN Newswire) - April 9, Hebe Biotechnology Pte Ltd (“Hebe Bio”), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company’s next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy designed to enhance efficacy and tolerability, addressing the global obesity challenge.

Strategic Leadership for a Transformative Therapy

Dr. Hentze brings over two decades of experience in pharmaceutical development, specializing in oncology, metabolic disorders, and biologics. His background spans academic research (IMCB, NTU), biotech ventures (S*BIO, ES Cell International, ASLAN), and large pharmaceutical players (Schering-Plough, MSD). Most recently, he served as Associate Director of Translational Sciences at EDDC (A*STAR).

At Hebe Bio, Dr. Hentze will spearhead preclinical and translational development, guiding clinical trial readiness, regulatory strategy, and strategic partnerships to accelerate the GLP-1 RA program’s global commercialization.

Sam Lim, MD, PhD, MBA, CEO of Hebe Bio, remarked, “We are thrilled to welcome Hannes to our leadership team. His deep expertise in metabolic drug development and his visionary approach align perfectly with our mission to deliver transformative therapies. His leadership will be pivotal as we accelerate our GLP-1 RA candidate, which has the potential to redefine standards in weight management and healthspan extension.”

Advancing Innovation in Metabolic Health

Hebe Bio’s GLP-1 RA therapy integrates cutting-edge science to optimize fat loss in the context of maintaining muscle mass, while minimizing common side effects associated with existing therapies. Preclinical data on Hebe Bio’s lead molecules have demonstrated superior efficacy and tolerability, positioning it as a next-generation solution for truly sustainable, healthspan-extending weight loss therapy.

Dr. Hentze expressed enthusiasm about his new role at Hebe Bio: “Joining Hebe Bio is a unique opportunity to make a real impact in a critical area of global health. Our GLP-1 RA candidate has the potential to shift the obesity treatment paradigm, and I look forward to collaborating with the exceptional Hebe Bio team, and our global partners to bring this therapy to patients worldwide.”

About Hebe Biotechnology Pte Ltd

Hebe Biotechnology is a Singapore-headquartered biopharmaceutical company dedicated to pioneering next-generation therapies for metabolic and chronic diseases. By combining advanced research with strategic global partnerships, Hebe Bio is committed to delivering patient-centric solutions that address unmet medical needs.

Media Contact:

Ms Kung
Bright International Communications Limited
Email: ir@brightcommns.com
Mobile: +852 4637 1627
Website: www.hebebio.sg



Topic: Press release summary Sectors: BioTech, Startups
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models  
July 10, 2025 23:00 HKT/SGT
The 10th Quam IR Awards was Successfully Held  
July 10, 2025 21:30 HKT/SGT
All-New MAZDA CX-5 Debuts in Europe  
Thursday, July 10, 2025 5:56:00 PM
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand  
Thursday, July 10, 2025 4:30:00 PM
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA  
July 10, 2025 12:30 HKT/SGT
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025  
July 10, 2025 07:30 HKT/SGT
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration  
July 10, 2025 07:00 HKT/SGT
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany  
July 9, 2025 22:00 HKT/SGT
Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK  
July 9, 2025 20:32 HKT/SGT
Standard Chartered GBA Business Confidence Survey points to further tariff drag in H2  
July 9, 2025 18:55 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575